BioSpace News Archive

Artificial intelligence and machine learning are increasingly becoming a part of drug discovery and development beginning with identifying new compounds to structuring and designing clinical trials and targeting clinical trial populations.

Gamida Cell Ltd. (Nasdaq: GMDA),will be presented during an oral session at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which is being held March 22 through March 25, 2020, in Madrid, Spain.

Alcon, the global leader in eye care and official sponsor of 20/20™, will debut key innovations at the SECO International 2020 meeting taking place March 4 – 8 at the Georgia World Congress Center in Atlanta, GA.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the fourth quarter and fiscal year ended December 31, 2019 on Monday, March 9, 2020.

POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines

La Jolla Pharmaceutical Company (Nasdaq: LJPC), today announced financial results for the three and twelve months ended December 31, 2019.

ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP) today announced that it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Memantine Hydrochloride Extended-Release Capsules 7 mg, 14 mg, 21 mg and 28 mg.

BridgeBio Pharma, Inc. (NASDAQ: BBIO), today is reporting its fourth quarter and full year 2019 financial results and recent progress across its portfolio

Valencia Technologies Corporation (" Valencia "), a private medical device company, today announced 6-month interim efficacy data from its eCoin Pivotal Clinical Trial.

Biocept, Inc. (NASDAQ: BIOC) (“Biocept” or the “Company”), today announced that it has entered into a securities purchase agreement with several institutional investors.